Trump FDA Nominee Heidi Overton Faces Senate Scrutiny Over Vaccine and Abortion Positions

Senate lawmakers will question Dr. Heidi Overton on Thursday as she seeks confirmation to lead the Food and Drug Administration, a role that would place her at the center of the administration's most contested health policy shifts. Overton, a physician and domestic policy adviser in the White House, has spent much of her career working for President Trump or conservative organizations aligned with his agenda. Those connections, and the policy positions she has advanced, are expected to dominate the hearing before the Senate Health, Education, Labor and Pensions Committee.

In her current role, Overton has worked on several White House health initiatives, including a revised food pyramid and efforts to overhaul childhood vaccination schedules. She previously served as an executive at the America First Policy Institute, where she authored papers critical of abortion access and transgender medical care for children. Before that, she was a White House fellow during Trump's first term.

If confirmed, Overton would inherit a series of controversial projects that mark sharp departures from longstanding FDA positions. The agency is conducting a safety review of mifepristone, the pill used in most U.S. abortions, following an order from Health Secretary Robert F. Kennedy Jr. The FDA first approved mifepristone in 2000 and has repeatedly affirmed its safety while expanding access, including mail delivery. Overton strongly criticized the 2023 decision to allow mail delivery, referring to it as "chemical abortion on demand."

She would also oversee a plan to break up combination vaccines — a policy Kennedy and Trump promoted in the Oval Office last month when they falsely suggested that using combination vaccines could contribute to autism. Committee chairman Sen. Bill Cassidy, a physician from Louisiana, called Overton's support for spacing out vaccinations "almost disqualifying." Cassidy and several Republican colleagues have simultaneously urged the FDA to restrict mifepristone access, creating a dynamic where vaccine skepticism may alienate the chair while abortion positions could align with much of the committee.

Overton's record on transgender care adds another dimension. She co-authored a 2024 article about then-vice presidential candidate Tim Walz titled "Tim Walz Made Minnesota A 'Sanctuary' For Baby Killers And Child Mutilators," criticizing Minnesota's policies on puberty-blocking drugs and gender-affirming surgeries for minors.

Two moderate Republicans on the panel — Maine Sen. Susan Collins and Alaska Sen. Lisa Murkowski — support federal abortion access and have bucked their party on the issue. Collins faces a tight reelection race where abortion is a central issue. Their votes could determine whether Overton secures the majority needed from the 21-member committee before advancing to the full Senate.

The FDA oversees U.S. medical products along with billions of dollars in food, cosmetics, tobacco, and vaping goods. The agency employs roughly 16,000 people across domestic and international locations. Overton has no experience running a large bureaucracy — a key skill for directing an agency that has lost about 20 percent of its workforce to layoffs, buyouts, retirements, or resignations since Trump took office.

Her predecessor, Dr. Marty Makary, resigned in May after a tenure defined by scientific disputes, leadership changes, and reports of low morale and internal dysfunction. Overton studied under Makary at Johns Hopkins University and earned a doctoral degree in clinical research after completing her medical degree at the University of New Mexico. Like Makary, she enters the role without administrative experience at scale.

The confirmation fight reflects competing demands within the administration: Trump's push to slash regulations on products such as vaping devices, and Kennedy's drive to scrutinize vaccines, drugs, and food ingredients. Overton's hearing will test whether a nominee closely tied to both agendas can navigate a Senate where vaccine policy and abortion access cut across party lines in unpredictable ways.